Correlation between KRAS genemutationandDTC resistance to 131I radiotherapy and prognosis / 中国肿瘤生物治疗杂志
FENG Zhiping; CHEN Fukun; YANG Chuanzhou; CHEN Ting; ZHU Jialun; LIU Chao; LV Juan; LU Jianmei; DENG Zhiyong.
Chinese Journal of Cancer Biotherapy
; (6): 213-219, 2019.
Artículo
en Zh
| WPRIM | ID: wpr-793103
@#
Objective:
To investigate the correlation between KRAS gene mutation and differentiated thyroid carcinoma (DTC) treatment effect and prognosis, and to explore the mechanism.Methods:
Clinical tissue samples from DTC patients undergoing 131I Radiotherapy were collected. Then single strand conformation polymorphism analysis of polymerase chain reaction products (PCRC-SSCP) was used to detect KRAS mutation rate in thyroid cancer patients of different TNM stages; p21 protein expression level was detected by real-time quantitative polymerase chain reaction (qPCR) and western blotting. DTC cells were treated by sub-lethal dose of 131I Radiotherapy, and then CCK-8 assay, transwell assay and flow cytometry (FCM) were used to evaluate the changes of cells viability. Animal models were then constructed for verification.Results:
The results showed that KRAS gene mutants were increased in 131I-resistant DTC patients; KRAS gene mutation suppressed p21 protein expression and was associated with clinical stage and poor prognosis. In vivo and in vitro experiments proved that sub-lethal dose of 131I increased KRAS gene mutation rate, suppressed p21 expression level, and caused 131I radiotherapy resistance. Reversely, over-expression of KRAS gene could significantly increase p21 expression, and inhibit tumor proliferation and metastasis.Conclusion:
KRAS gene mutations were associated with DTC TNM stages and 131I resistance in DTC patients. Sub-lethal dose of 131I treatment could improve 131I resistance in DTC cells line, inversely, over-expressed KRAS gene could increase the sensitivity to 131I radiotherapy in DTC patients.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados